Efgartigimod is Safe and Effective in Previously Refractory AChR Myasthenia Gravis Patients

In this MEDtalk, Jennifer Spillane, a neurology consultant from the National Hospital for Neurology, Queen Square and Guys and St. Thomas’, discusses data from the UK’s Early Access to Medicine Scheme for efgartigimod, a treatment for myasthenia gravis. Jennifer highlights the data collection process, patient characteristics, treatment outcomes, and the overall efficacy and safety of efgartigimod.